Drugs / TTP273
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02653599 | Dec 2015 → Nov 2016 | type 2 diabetes mellitus | vTv Therapeutics | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2017-06-11 | vTv Therapeutics | Results vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions vtvtherapeutics.com ↗
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of Type 2 diabetes, were presented at the American Diabetes Association 77 th Scientific Sessions. |
| 2016-12-14 | vTv Therapeutics | Results vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes vtvtherapeutics.com ↗
TTP273 demonstrated a statistically significant reduction in HbA1c. |
| 2016-04-20 | vTv Therapeutics | Results vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity vtvtherapeutics.com ↗
Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects |
| 2016-02-22 | vTv Therapeutics | Results vTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273 vtvtherapeutics.com ↗
Data presented showed that TTP273, vTv’s orally bioavailable GLP-1R agonist currently being evaluated in a Phase 2 trial, shows “functional selectivity” for a particular subset of the full GPCR signaling repertoire. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTP273 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02653599 ↗ |
| Route | Oral | “administered orally” NCT02653599 ↗ |